R B Van Dyke
Overview
Explore the profile of R B Van Dyke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jao J, Yu W, Patel K, Miller T, Karalius B, Geffner M, et al.
HIV Med
. 2017 Nov;
19(3):175-183.
PMID: 29159965
Objectives: Dyslipidaemia is common in perinatally HIV-infected (PHIV) youth receiving protease inhibitors (PIs). Few studies have evaluated longitudinal lipid changes in PHIV youth after switch to newer PIs. Methods: We...
2.
Miller T, Borkowsky W, DiMeglio L, Dooley L, Geffner M, Hazra R, et al.
HIV Med
. 2011 Dec;
13(5):264-75.
PMID: 22136114
Objectives: HIV-infected children may be at risk for premature cardiovascular disease. We compared levels of biomarkers of vascular dysfunction in HIV-infected children (with and without hyperlipidaemia) with those in HIV-exposed,...
3.
Kline M, Van Dyke R, Lindsey J, Gwynne M, Culnane M, Diaz C, et al.
Pediatrics
. 1999 May;
103(5):e62.
PMID: 10224206
Objectives: To evaluate the safety, tolerance, and antiviral activity of combination therapy with stavudine (d4T) plus didanosine (ddI) in symptomatic human immunodeficiency virus (HIV)-infected children. Methods: The study enrolled HIV-infected...
4.
Kline M, Blanchard S, Fletcher C, Shenep J, McKinney Jr R, Brundage R, et al.
Pediatrics
. 1999 Apr;
103(4):e47.
PMID: 10103339
Objectives: To evaluate the pharmacokinetic features, safety, and tolerance of abacavir, given alone and in combination with other nucleoside antiretroviral agents, in symptomatic human immunodeficiency virus (HIV)-infected children. Methods: HIV-infected...
5.
Van Dyke R, Korber B, Popek E, Macken C, Widmayer S, Bardeguez A, et al.
J Infect Dis
. 1999 Jan;
179(2):319-28.
PMID: 9878014
In a prospective cohort study, clinical and biologic factors that contribute to maternal-child transmission of human immunodeficiency virus type 1 (HIV-1) were studied. HIV-infected pregnant women and their infants were...
6.
Sperling R, Shapiro D, McSherry G, Britto P, Cunningham B, Culnane M, et al.
AIDS
. 1998 Oct;
12(14):1805-13.
PMID: 9792381
Objective: To determine the safety of the zidovudine (ZDV) regimen utilized in the Pediatric AIDS Clinical Trial Group (ACTG) 076 study. Design: ACTG 076 was a randomized, double-blind, placebo-controlled trial...
7.
Kline M, Van Dyke R, Lindsey J, Gwynne M, Culnane M, McKinney Jr R, et al.
Pediatrics
. 1998 Jan;
101(2):214-20.
PMID: 9445494
Objectives: To compare the safety and tolerance of stavudine (d4T) versus zidovudine (ZDV, AZT) in symptomatic human immunodeficiency virus-infected children 3 months to 6 years of age. Methods: In an...
8.
Sperling R, Shapiro D, Coombs R, Todd J, Herman S, McSherry G, et al.
N Engl J Med
. 1996 Nov;
335(22):1621-9.
PMID: 8965861
Background And Methods: A placebo-controlled trial has shown that treatment with zidovudine reduces the rate at which human immunodeficiency virus type 1 (HIV-1) is transmitted from mother to infant. We...
9.
Estrada B, Silio M, Begue R, Van Dyke R
Pediatr Infect Dis J
. 1996 Aug;
15(8):720-1.
PMID: 8858685
No abstract available.
10.
Van Dyke R, Heneine W, Perrin M, Rudolph D, Starszak E, Woods T, et al.
J Pediatr
. 1995 Dec;
127(6):924-8.
PMID: 8523190
Objective: To determine the frequency of mother-to-child transmission of human T-lymphotropic virus type II (HTLV-II) and to explore its association with breast-feeding. Design: Prospective study of children born to a...